National Comprehensive Cancer Network

NCCN Oncology Research Program (ORP)
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources (Members Only
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Guidelines, Compendium for NHL Updated to Include Ofatumumab and Romidepsin

The NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkin's Lymphomas (NHL) and the NCCN Drugs & Biologics Compendium chapter for NHL have been updated to include ofatumumab and romidepsin.

Ofatumumab was added to the NCCN Guidelines as a treatment option for relapsed/refractory disease in patients with chronic lymphocytic leukemia (CLL), with and without a 17p deletion.

In addition, the updated NCCN Guidelines now include romidepsin as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome, two of the most common types of cutaneous T-cell lymphoma (CTCL).